

Trans-COST Actions initiative on COVID-19

Chiara Riganti, MD
Departmen to Oncology, University of Torino, Italy
Email: chiara.riganti@unito.it

Chair of COST Action 17104-STRATAGEM Website: https://stratagem-cost.eu/

COVID-19 Task force

Prof- Helena Vasconcelos, University of Porto, Portugal https://www.ncelos@ipatimup.pt

Dr. Thomas Mohr,
ScieceConsult, Vienna Austria
thomas.mohr@mohrkeg.co.at


The reaction of scientists towards the first wave in Europe

Need to do "something" Need to discover "something"


Unprecedented funding

Did we succeed in containing COVID19 pandemics?

Spanish flu pandemics (1918)



COVID-19 pandemics (2020)



4 pieces of evidences of lack of coordinated action among scientists



Lack of accessible and comprehensive multi-national platforms to facilitate interdisciplinary discussion and collaboration



Scattering of reliable scientific information




Lack of **coordination between laboratories** with complementary expertise and resources



Limited **sharing of information** on COVID-19 that single research institutions and hospitals started to collect

A possible solution...?

Organising an inclusive platform to allow inter- and trans-disciplinary networking on emerging infectious diseases



reciprocal benefits for scientists and stakeholders against future waves of COVID-19

Exploiting COST Action to create such transdisciplinary network...?





Scientists focused on a scientific problem

+

Multiple and complementary expertise

+


Open access to the network

Multidisciplinarity & Flexibility




Trans-COST Actions network joining expertise against COVID-19

Beginning and progress of Trans-COST Actions network



Operation mode of Trans-COST Actions network



April 2020





Survey of expertise





Periodic meetings



6 Working Groups

PRO-ACTIVE COLLABORATIONS




- 1) Epidemiology
- 2) Prevention
- 3) Viral pathogenesis
- 4) Diagnosis and treatment
- 5) Vaccines and immunological studies
- 6) New drug development for treatment



Collaborations within Trans-COST Actions network: some examples


Basic research

- Cellular models
- Techniques to monitor adhesion/proliferation/ cell damage
- Drug-targets prediction
- Virtual drug screening
- Drug synthesis
- Antimicrobial solutions
- Biomarkers discovery
- Computational modelling
- Artificial intelligence



First results of Trans-COST Actions network

1) Scientific publications



- 2) Open Access software
- COVEX software: https://exbio.wzw.tum.de/covex/



Drug Repositioning And Cooperation Database (DRACD): https://dracdb.mohrkeg.co.at/dracdb

3) COVID-19 mitigation national recommendations

4) Grants applications

Cooperation with other networks

ECRIN-European Clinical Research Infrastructure Network Dariah-EU societal and human of impacts of COVID-19

American Lung Association

Network Medicine Alliance and Institute Trans-COST Action Network

Global Health Platform

The Institute Pasteur International Network Collective Effort

CLAIRE - Confederation of Laboratories for Artificial Intelligence Research in Europe

The goals of Trans-COST Actions network

- drafting a roadmap of disciplines present in the network to identify the right expertise needed to mount a faster responses to emergencies
- creating a **network of laboratories** able to **quickly "switch" their work** toward the diagnosis, treatment and prevention of SARS-CoV2 infection
- building a core set of trans-disciplinary tools, available to the scientific community to aid research into COVID-19 and future pandemics

Exploiting the tools and resources

present in the network






To gather available clinical and epidemiological data

To develop **new pharmacological strategies** and **new anti-microbial solutions** to treat and prevent COVID-19 infection

Welcome to our Trans-COST Action network...and Mega-network



We are flexible and open...new expertise are WELCOME!